Open AccessThe role of sarcopenia in the development of non-alcoholic fatty liver disease
Author(s) -
В. Б. Гриневич,
Е. И. Сас
Publication year - 2020
Publication title -
èksperimentalʹnaâ i kliničeskaâ gastroènterologiâ
Language(s) - English
Resource type - Journals
ISSN - 1682-8658
DOI - 10.31146/1682-8658-ecg-183-11-70-73
Subject(s) - sarcopenia , medicine , fatty liver , metabolic syndrome , skeletal muscle , disease , muscle disease , bioinformatics , muscle mass , alcoholic liver disease , intensive care medicine , obesity , cirrhosis , biology
Currently, a large number of studies have been published supplementing our knowledge of sarcopenia and its eect on the development of metabolic disorders, including the formation of NAFLD. This data allows a new look at the pharmacological and non-pharmacological approaches to the treatment of NAFLD, based on basic physiological processes, including the biological axis of the muscle — the liver. This provides a compelling rationale for studying skeletal muscle as the main therapeutic target for NAFLD and metabolic syndrome.